Soleno Therapeutics Q3 EPS $(0.95) Misses $(0.58) Estimate
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics reported Q3 losses of $0.95 per share, missing the analyst consensus estimate of $0.58 by 63.79%. This represents a 25% increase in losses compared to the same period last year.
November 07, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Soleno Therapeutics' Q3 losses were significantly higher than expected, which could negatively impact investor sentiment and the company's stock price in the short term.
Soleno Therapeutics reported higher than expected losses for Q3, missing the analyst consensus estimate by a significant margin. This could lead to a decrease in investor confidence and a potential drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100